PTEN基因表达与腮腺多形性腺瘤的发生发展的关系

目的 分析PTEN基因表达与腮腺多形性腺瘤的发生发展的关系。方法选取本院口腔科收治的腮腺多形性腺瘤25例,同时选取正常腮腺组织20例作为对照,分别采集腮腺多形性腺瘤患者的腺瘤组织、瘤旁0.5 cm～2 cm组织、舌下腺组织,以及正常对照的腮腺组织,比较不同组织中PTEN mRNA及蛋白的表达差异;比较复发组、未复发组和正常腮腺组织中PTEN mRNA及蛋白的表达差异。结果腺瘤组织、瘤旁0.5 cm组织、瘤旁1 cm组织、瘤旁1.5 cm组织中PTEN mRNA表达均低于正常腺体组织和舌下腺组织;腺瘤组织(56.0%)和瘤旁0.5 cm组织(64.0%)中PTEN蛋白表达阳性率均低于正常腺体组织(100.0%)和舌下腺组织(96.0%);复发组腺瘤组织中PTEN mRNA表达(0.413±0.052)均低于正常腺体组织(0.947±0.061)和未复发组腺瘤组织(0.639±0.058);复发组腺瘤组织中PTEN蛋白表达阳性率(27.3%)均低于正常腺体组织(100.0%)和未复发组腺瘤组织(71.4%)(P均<0.05)。结论腮腺多形性腺瘤组织中的PTEN表达低于正常腮腺和舌下腺组织,复发组腺瘤组织中的PTEN表达低于未复发组和正常组。     

分化型甲状腺癌手术联合~(131)Ⅰ清甲治疗后复发与乏氧诱导因子-lα表达的关系

目的:研究分化型甲状腺癌手术联合131I清除剩余甲状腺(清甲)治疗后复发与乏氧诱导因子-1α(HIF-1α)表达的相关性,探讨HIF-1α对治疗后复发的可能机制。方法:依据甲状腺球蛋白(Tg)、甲状腺球蛋白抗体(TgAb)、B超、X线及全身131I显像的复发判定标准,观察分析173例分化型甲状腺癌手术联合131I清甲治疗成功后3年复发率,将复发病例作为复发组;随机选取相同数量未复发病例作为无复发组。采用免疫组织化学法和RT-PCR技术检测复发组和无复发组患者癌组织中HIF-1α阳性细胞率和HIF-1α基因表达水平。结果:分化型甲状腺癌手术联合131I清甲治疗成功后3年内复发率为5.20%(9/173)。其中乳头状癌复发率为4.90%(5/102),滤泡状癌复发率为5.63%(4/71),2组间比较差异无显著性(P>0.05)。复发组乳头状癌和滤泡状癌组织HIF-1α阳性细胞率和HIF-1α基因表达水平明显高于无复发组(P<0.05)。结论:分化型甲状腺癌手术联合131I清甲治疗成功后仍有少数患者复发,其机制之一可能与癌组织中HIF-1α表达水平明显增高有关。     

Cumulative Recurrence Rate and Risk Factors for Recurrent Abdominal Wall Endometriosis after Surgical Treatment in a Single Institution

PurposeThis study aimed to evaluate the cumulative recurrence rate and risk factors for recurrent abdominal wall endometriosis (AWE) after surgical treatment.Materials and MethodsA retrospective cohort study was conducted at a single gynecological surgery center between January 2004 and December 2020. Patients who were surgically treated and followed up for at least 6 months after surgery were selected.ResultsEighteen patients with pathologically diagnosed AWE were included in this study. The median follow-up duration was 22.5 months (range, 6–106). The median age was 37 years (range, 22–48), and 33.3% of the patients were nulliparous. Among the patients included in our study, 55.6% complained of a mass with cyclic pain, and 27.8% had a palpable mass. In addition, 22.2% of patients experienced recurrence with 17.5±9.7 months of mean time to recurrence. The cumulative recurrence rates at 24 and 60 months after surgical treatment of AWE were 23.8% and 39.1%, respectively. There were no statistically significant risk factors for the recurrence of AWE, including postoperative medical treatment.ConclusionThe recurrence rate of AWE appears to be correlated with the follow-up duration. There was no statistically significant risk factor for the recurrence of AWE. Unlike ovarian endometriosis, postoperative hormonal treatment does not seem to lower the recurrence of AWE. The findings of the current study may help healthcare providers in counselling and managing patients with AWE.     

高血压性脑出血再发危险因素的临床研究

目的 :探讨高血压性脑出血再发危险因素。方法 :对收治的 6 1例高血压性脑出血再发患者进行回顾性分析。结果 :高血压性脑出血的再发率为 7.2 9% ,再次出血的临床表现较首次重 ,出血量较首次大 ,合并症较首次多 ,病死率明显升高 ;再次出血组与一次出血组的血压中平均收缩压无显著差异 (P>0 .0 5 ) ,但舒张压大于 90、95 mm Hg、收缩压大于 2 0 0 mm Hg及舒张压大于 95 mm Hg同时收缩压大于 2 0 0 mm Hg病例中 ,均与一次出血组存在极显著差异 (P<0 .0 1)。结论 :抓好血压的管理 ,是预防高血压性脑出血再发的关键。     

肝脏移植术后乙肝复发的综合防治

乙肝终末期肝病患者肝脏移植术后乙肝复发是影响患者长期存活的重要因素.本文重点介绍肝脏移植术后乙肝复发的机制及影响因素;提出肝脏移植术后乙型肝炎病毒再感染及乙肝复发的诊断标准;探讨预防乙肝复发的各种方案的优劣,指出拉米夫定联合小剂量乙肝免疫球蛋白联合用药方案是目前报道的最为有效的预防方案.笔者认为,肝脏移植术后乙肝复发需进行综合防治,治疗从移植前开始进行,贯穿术中,术后进行长期乃至终生防治.     

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence

Background/AimsMany patients with Crohn’s disease (CD) undergo intestinal resection during the disease course. Despite surgery, postoperative recurrence (POR) commonly occurs. Although postoperative use of tumor necrosis factor α (TNF-α) inhibitors is known to be effective in preventing POR, few studies have evaluated the effectiveness of continuing the same TNF-α inhibitors postoperatively in patients who received TNF-ɑ inhibitors before surgery.MethodsThis retrospective observational study was performed in a single tertiary medical center. We retrospectively reviewed patients who had undergone the first intestinal resection due to CD and divided them into two groups TNF-α inhibitor users in both the preoperative and postoperative periods, and TNF-α inhibitor users in only the preoperative period. We compared the clinical outcomes between these two groups.ResultsIn total, 45 patients who used TNF-α inhibitors preoperatively were recruited. Among them, TNF-α inhibitors were used postoperatively in 20 patients (44.4%). The baseline characteristics except age at diagnosis were similar in both groups. The rates of surgical and endoscopic recurrence were not different between the two groups, but the cumulative clinical recurrence rate was significantly lower in the postoperative TNF-α inhibitors group (log-rank p=0.003). In multivariate Cox regression analysis, postoperative TNF-α inhibitors use was significantly associated with a decreased risk of clinical recurrence (adjusted hazard ratio, 0.204; 95% confidence interval, 0.060 to 0.691; p=0.011).ConclusionsContinuing TNF-α inhibitors postoperatively in patients who were receiving TNF-α inhibitors before surgery significantly reduced the rate of clinical recurrence. For patients with CD who received TNF-α inhibitors preoperatively, continuing their use after surgery could be recommended.     

Prediction of early recurrence of hepatocellular carcinoma after resection based on Gd-EOB-DTPA enhanced magnetic resonance imaging: a preliminary study

BackgroundEarly recurrence (ER) after radical resection of hepatocellular carcinoma (HCC) affects the prognosis of patients. Gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) can improve the detection rate of small HCC. This study innovatively introduces a new quantitative index combined with qualitative index to compare the differences in clinical and imaging characteristics between ER and non-ER groups and evaluate the feasibility of Gd-EOB-DTPA-enhanced MRI in predicting ER.MethodsA total of 68 patients with HCC confirmed by operation and pathology in the Shandong Cancer Hospital and Institute were included retrospectively. All participants were examined by Gd-EOB-DTPA-enhanced MRI within 3 weeks before surgery. Regular follow-up was performed every 2 months within 1 year after operation. Among them, 18 cases with new lesions were in ER group, and 50 cases without new lesions were in non-ER group. The clinical and imaging data of the 2 groups were collected, and the differences of clinical data and preoperative MRI signs between the ER group and non-ER group were compared. The predictive factors of ER after HCC were analyzed by multivariate logistic regression.ResultsThe quantitative parameter lesion-to-liver contrast enhancement ratio (LLCER) can predict the pathological grade of HCC (P=0.023). The results of univariate analysis between the ER group and non-ER group showed that there were significant differences in pathological grade (P=0.008), lesion morphology (P=0.011), peritumoral low signal intensity in hepatobiliary phase (HBP) (P<0.001), satellite nodules (P<0.001), and LLCER (P<0.001) between the 2 groups. Multivariate logistic regression analysis showed that HBP peritumoral low signal intensity [odds ratio (OR) =7.214, 95% confidence interval (CI): 1.230–42.312, P=0.029], satellite nodules (OR =9.198, 95% CI: 1.402–60.339, P=0.021), and parameter LLCER value (OR =0.906, 95% CI: 0.826–0.995, P=0.039) were independent predictors of ER of HCC after resection.ConclusionsPreoperative Gd-EOB-DTPA enhanced MRI has important predictive value for early recurrence after radical resection of hepatocellular carcinoma.